

# **Novel combination of sorafenib and biochanin-A synergistically enhances the anti-proliferative and pro-apoptotic effects on hepatocellular carcinoma cells**

**Mohieldin M. Youssef<sup>1,2</sup>, Mai F. Tolba<sup>3</sup>, Eman El-Ahwany<sup>4</sup>, Amani E. Khalifa<sup>3</sup>,  
Suher Zada<sup>1</sup> and Ashraf B. Abdel-Naim<sup>3\*</sup>**

<sup>1</sup> The American University in Cairo, New Cairo, Egypt 11835

<sup>2</sup> Pharmacology and Toxicology department, Faculty of Pharmacy, Egyptian-Russian University, Cairo, Egypt 11829

<sup>3</sup> Pharmacology and Toxicology department, Faculty of Pharmacy, Ain-Shams University, Cairo, Egypt 11566

<sup>4</sup> Immunology Department, Theodor-Bilharz Research Institute (TBRI), Giza, Egypt 12411

*\*Corresponding Author:*

Dr. Ashraf B. Abdel-Naim

Professor of Pharmacology and Toxicology

Faculty of Pharmacy, Ain-Shams University.

Cairo, Egypt 11835

E-mail: [abnaim@pharma.asu.edu.eg](mailto:abnaim@pharma.asu.edu.eg)

Cell: +2 01119998505

**Supplementary Table 1: Synergy analysis of SOR/Bio-A combination ratio 1:4 in HepG2 cancer cell line using Calcusyn software.**

| Bio-A ( $\mu$ M) | SOR ( $\mu$ M) | Fa    | CI     |
|------------------|----------------|-------|--------|
| 0.04             | 0.01           | 0.07  | 0.550  |
| 0.12             | 0.03           | 0.04  | 3.756  |
| 0.4              | 0.1            | 0.092 | 3.647  |
| 1.2              | 0.3            | 0.164 | 4.401  |
| 4                | 1              | 0.254 | 6.922  |
| 12               | 3              | 0.377 | 9.629  |
| 40               | 10             | 0.546 | 13.281 |
| 120              | 30             | 0.607 | 29.307 |
| 400              | 100            | 0.745 | 46.983 |

**Supplementary Table 2: Synergy analysis of SOR/Bio-A combination ratio 1:16 in HepG2 cancer cell line using Calcusyn software.**

| Bio-A ( $\mu$ M) | SOR ( $\mu$ M) | Fa    | CI    |
|------------------|----------------|-------|-------|
| 16               | 1              | 0.259 | 7.552 |
| 48               | 3              | 0.993 | 0.442 |
| 160              | 10             | 0.998 | 0.836 |
| 480              | 30             | 0.999 | 1.041 |

**Supplementary Table 3: Dose reduction index (DRI) for SOR/Bio-A 1:50 combination ratio in HepG2 cancer cell line using Calcusyn software.**

| Fa    | Drug alone          |                   | Dose Reduction Index (DRI) |         |
|-------|---------------------|-------------------|----------------------------|---------|
|       | Bio-A<br>( $\mu$ M) | SOR<br>( $\mu$ M) | Bio-A                      | SOR     |
| 0.17  | 8.0602              | 0.1994            | 53.735                     | 66.468  |
| 0.24  | 10.1888             | 0.3706            | 20.378                     | 37.058  |
| 0.283 | 11.4964             | 0.5100            | 7.664                      | 16.999  |
| 0.425 | 16.1452             | 1.2518            | 3.229                      | 12.518  |
| 0.708 | 30.7128             | 6.8558            | 2.048                      | 22.853  |
| 0.985 | 183.1680            | 770.6528          | 3.663                      | 770.653 |

**Supplementary Figure 1: Representative western blot for the effect of SOR/Bio-A combination on protein expression of Bax in HepG2 cells treated for 72 h**

